Pancreatic Cancer Research

ResearcherLMU KlinikumActive in the last 2 years

Maximilian Niyazi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7711-9486; OpenAlex author ID A5065547065. Sources: ClinicalTrials.gov.

Their work

Papers
8 (first author 1, last author 0)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
36
Papers, trials and grants by year

2016: 2 papers · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 trial · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 2 papers

Papers 8

  1. Improved PTV coverage and OAR sparing with stereotactic MRI-guided online adaptive radiotherapy with elective fields in pancreatic cancer. Co-author DOI 10.1016/j.tipsro.2025.100354↗
  2. Sustained Clinical Response to Olaparib in a Patient with Metastatic Pancreatic Cancer and Somatic ATM Mutation R2034Ter: A Case Report. Co-author DOI 10.1159/000545975↗
  3. Stereotactic body radiotherapy for pancreatic cancer - A systematic review of prospective data. Co-author DOI 10.1016/j.ctro.2024.100738↗
  4. Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. Co-author DOI 10.1007/s11523-023-00950-0↗
  5. MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open rand… First author DOI 10.1186/s13014-022-01988-6↗
  6. Role of stereotactic body radiation in the enhancement of the quality of life in locally advanced pancreatic adenocarcinoma: a systematic review. Co-author DOI 10.1186/s13014-022-02076-5↗
  7. Stereotactic body radiotherapy for renal cell cancer and pancreatic cancer : Literature review and practice recommendations of the DEGRO Working Group on Stere… Co-author DOI 10.1007/s00066-016-1053-1↗
  8. Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer. Co-author DOI 10.1016/j.pan.2016.03.016↗

Trials 1

  1. MR-Guided Adaptive SBRT of Primary Tumor for Pain Control in Metastatic PDAC Principal investigator NCT05114213↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Georg Beyer · 5 shared papers, 2022–2025 · strength 0.82
  2. Marlies Vornhülz · 4 shared papers, 2022–2025 · strength 0.69
  3. Julia V. Mayerle · 4 shared papers, 2022–2025 · strength 0.62
  4. Paul Rogowski · 3 shared papers, 2024–2025 · strength 0.61
  5. Christoph Benedikt Westphalen · 4 shared papers, 2016–2025 · strength 0.59
  6. Mohamed A. Shouman · 2 shared papers, 2024–2025 · strength 0.41
  7. Volker Heinemann · 3 shared papers, 2016–2025 · strength 0.39
  8. Kathrin Heinrich · 2 shared papers, 2023–2025 · strength 0.34
  9. Matthias Gückenberger · 2 shared papers, 2016–2022 · strength 0.21
  10. Simon Sirtl · 1 shared paper, 2025 · strength 0.21
  11. Alexander Kleger · 1 shared paper, 2025 · strength 0.21
  12. Dinah Konnerth · 1 shared paper, 2025 · strength 0.20
  13. Michael Haas · 2 shared papers, 2016–2023 · strength 0.18
  14. Steffen Ormanns · 2 shared papers, 2016–2023 · strength 0.18
  15. Jens Werner · 2 shared papers, 2016–2023 · strength 0.18
  16. Stefan Hubert Boeck · 2 shared papers, 2016–2023 · strength 0.18
  17. Ivonne Regel · 1 shared paper, 2022 · strength 0.15
  18. Péter Jenő Hegyi · 1 shared paper, 2022 · strength 0.15
  19. Matea Pavic · 1 shared paper, 2022 · strength 0.13
  20. Jürgen Debus · 1 shared paper, 2022 · strength 0.13
  21. Ralph Fritsch · 1 shared paper, 2022 · strength 0.13
  22. Danmei Zhang · 1 shared paper, 2023 · strength 0.13
  23. Bernhard Willibald Renz · 1 shared paper, 2023 · strength 0.13
  24. Elisabetta Goni · 1 shared paper, 2023 · strength 0.13
  25. Jan Goesta D’Haese · 1 shared paper, 2023 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.